We use cookies on this site to enable your digital experience. By continuing to use this site, you are agreeing to our cookie policy. close

FDA Approves First Non-Hodgkin's Lymphoma Biosimilar

Law360 (November 28, 2018, 6:26 PM EST) -- The U.S. Food and Drug Administration on Wednesday approved Celltrion and Teva’s version of the blockbuster cancer treatment Rituxan, marking the first biosimilar approved in the U.S. to treat non-Hodgkin’s lymphoma....
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.